Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » CMIC HOLDINGS Co., Ltd.

CMIC HOLDINGS Co., Ltd.

Table of Contents
Table of Contents

CMIC HOLDINGS Co., Ltd. leverages their experience of more than 30 years and know-how as a CRO(contract research organization) to provide customizable services to meet clients’ diverse needs. This page show-cases the key features of CMIC’s non-clinical study services, examples of disease models, and related case studies. We hope it serves as a reference when you select a CRO for non-clinical research.

Features of CMIC HOLDINGS Co., Ltd.’s Non-Clinical Study Services

High-Quality Studies

CMIC HOLDINGS Co., Ltd. conducts high-quality non-clinical studies in compliance with Good Laboratory Practice (GLP) standards. The company provides highly reliable data in pharmacodynamic and pharmacokinetic studies by evaluating the safety under strict quality control.

Extensive Experience and Expertise

With a strong track record in contract research, CMIC HOLDINGS Co., Ltd. offers flexible solutions tailored to a wide range of research needs. The company has collaborated with many pharmaceutical and biotech firms, providing extensive consulting and scientific support.

Diverse Animal Models

CMIC HOLDINGS Co., Ltd. offers a wide range of animal models for specific therapeutic areas. They have a laboratory infrastructure that allows for accurate evaluation efficacy, and new models can also be developed if requested.

Examples of Disease Models Maintained by CMIC HOLDINGS Co., Ltd.

It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.

However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.

Below are some examples of disease models offered at Ina Research.

Allergic Rhinitis Model

Guinea pigs sensitized with OVA are used to evaluate drug effects on acute/chronic nasal reactions—such as rhinitis and nasal obstruction—induced by intranasal antigen administration, as well as on inflammatory cell infiltration in the nasal cavity.
Rats can also be used for efficacy studies on increased vascular permeability in the nasal mucosa.

Asthma Model

Guinea pigs sensitized with OVA are used to examine drug effects on acute/chronic asthmatic reactions and airway obstruction induced by antigen inhalation, as well as on inflammatory cell infiltration in the airway lumen.
Mouse models are also available to investigate airway hyperresponsiveness and airway remodeling.

Non-Clinical Study Cases by CMIC HOLDINGS Co., Ltd.

No case studies are currently listed on the official website.

Corporate Information

Backed by extensive experience in non-clinical research, CMIC HOLDINGS Co., Ltd. provides comprehensive services ranging from new drug development planning to preparation of regulatory submission documents.

Address 1-1-1 Shibaura, Minato-ku, Tokyo, Japan
Tel 03-6779-8000
Website https://www.cmicgroup.com/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services